 |
196 Products |  |
52 Diseases | | 196 Products |
|
3529 Trials |  |
15381 News |  |
| «12...2021222324252627282930...208209» |
- Irene (pyrotinib) / Jiangsu Hengrui Pharma, Herceptin (trastuzumab) / Roche
Trastuzumab Combined with Pyrotinib and Capecitabine as Postoperative Adjuvant Therapy in Non-Pathological Complete Response HER2-Positive Early Breast Cancer Following Neoadjuvant Therapy: A Multicenter Phase II Study (Exhibit Hall) - Oct 30, 2025 - Abstract #SABCS2025SABCS_1471;
P2
The overall safety profile of the regimen was acceptable, with no new safety signals identified. Primary prophylaxis with loperamide effectively reduced the incidence of grade ?3 diarrhea during adjuvant therapy with pyrotinib.
- AiRuiKang (dalpiciclib) / Jiangsu Hengrui Pharma
Dalpiciclib Combined with Letrozole as Neoadjuvant Therapy for Stage II-III HR-Positive, HER2-Negative Breast Cancer: A Phase II Study (Exhibit Hall) - Oct 30, 2025 - Abstract #SABCS2025SABCS_1383;
P2
These results support its potential as a fully oral, chemotherapy-free neoadjuvant regimen. Further studies are warranted to confirm these preliminary results.
- Precision neoadjuvant treatment with Artificial Intelligence assisted subtyping in HR+/HER2- breast cancer: a randomized, open-label, phase 2 trial FASCINATE-N (Exhibit Hall) - Oct 30, 2025 - Abstract #SABCS2025SABCS_1375;
P2
NET plus CDK4/6 inhibitor was verified to replace chemotherapy with better tolerance in the endocrine-base group while precision therapy was proved promising clinical activity and manageable safety profile in the targeted-based group. (ClinicalTrials.gov: NCT05582499).
- AiRuiKang (dalpiciclib) / Jiangsu Hengrui Pharma
An Exploratory Clinical Trial of CDK4/6 Inhibitor Dalpiciclib Combined with Aromatase Inhibitors as Neoadjuvant Therapy for Stage II-III HR-positive HER2-negative Breast Cancer (Exhibit Hall) - Oct 30, 2025 - Abstract #SABCS2025SABCS_1351;
Conclusion Dalpiciclib combined with AIs demonstrates promising efficacy and manageable toxicity as neoadjuvant therapy for stage II-III HR+/HER2- breast cancer, offering a new chemotherapy-free option. Future research should focus on biomarker-guided patient selection, long-term outcomes assessment, and comparative trials with other neoadjuvant therapies, aiming to improve the treatment paradigm for HR+/HER2- breast cancer.
- AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / HLB Bio Group
Exploratory phase II trial of camrelizumab (an anti-PD-1 antibody) combined with apatinib (a VEGFR-2 inhibitor) and chemotherapy as a neoadjuvant therapy for triple-negative breast cancer (NeoPanDa03): efficacy, safety and biomarker analysis (302 ABC) - Oct 30, 2025 - Abstract #SABCS2025SABCS_1159;
P2
In conclusion, camrelizumab and apatinib combined with chemotherapy have good clinical efficacy and good safety as neoadjuvant treatments for stage II-III TNBC, warranting further investigation and potential clinical application. This innovative dual-score system stratifies pretreatment prognosis (PRPscore) and dynamically evaluates therapeutic efficacy (EAscore), enabling precision neoadjuvant optimization.
- AiRuiKang (dalpiciclib) / Jiangsu Hengrui Pharma
Ki-67-guided stratification and resistance mechanism analysis of CDK4/6 inhibitor therapy following adaptiveneoadjuvant endocrine treatment in HR+/HER2? breast cancer (Exhibit Hall) - Oct 30, 2025 - Abstract #SABCS2025SABCS_565;
P4
The malignant epithelial C2 cell cluster and FUT6 were identified as potential therapeutic targets associated with CDK4/6i resistance. Moreover, persistent or emerging PIK3CA and TP53 mutations during adaptive therapy may serve as molecular indicators of resistance to sequential AI and CDK4/6i treatments.
- Chemotherapy-free neoadjuvant strategy in HR+/HER2- breast cancer: CDK4/6 inhibitors plus endocrine therapy show comparable efficacy to chemotherapy-sequenced approach (Exhibit Hall) - Oct 30, 2025 - Abstract #SABCS2025SABCS_545;
These results support the feasibility of chemotherapy-free neoadjuvant strategies for select HR+/HER2? patients, potentially minimizing chemotherapy-related toxicity without compromising treatment efficacy.
- | AiSuTe (tegileridine) / Jiangsu Hengrui Pharma
New trial: Comparison of the 95% Effective Dose (ED95) and Efficacy between Tegileridine Fumarate and Fentanyl in Hysteroscopic Surgery: A Prospective, Multicenter, Randomized Controlled Trial (EUDRACT) - Oct 30, 2025
P=N/A, N=182, Not yet recruiting, Sponsor: First Affiliated Hospital of Gannan Medical University; First Affiliated Hospital of Gannan Medical University
- | Avastin (bevacizumab) / Roche, AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma
New P2 trial: A Phase II Single-Arm Prospective Clinical Study of Adebrelimab Combined with Chemotherapy With or Without Bevacizumab as First-Line Treatment for Recurrent/Persistent/Metastatic Cervical Cancer (EUDRACT) - Oct 30, 2025
P2, N=50, Not yet recruiting, Sponsor: First Hospital Of Nanping; First Hospital Of Nanping
- | AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma
New trial, IO biomarker: Adebrelimab combined with TCb-AC (albumin paclitaxel+carboplatin doxorubicin+cyclophosphamide) neoadjuvant therapy for early or locally advanced triple negative breast cancer:a single arm study (EUDRACT) - Oct 30, 2025
P=N/A, N=20, Completed, Sponsor: Yuncheng Central Hospital; Yuncheng Central Hospital
- | AiRuiKang (dalpiciclib) / Jiangsu Hengrui Pharma
New P4 trial: Efficacy and safety of Dalpiciclib in combination with endocrine adjuvant therapy for middle/high-risk HR-positive early stage breast cancer: a multicenter, prospective clinical study (EUDRACT) - Oct 30, 2025
P4, N=2000, Recruiting, Sponsor: Jilin Cancer Hospital; Jilin Cancer Hospital
- | HRS-9821 / GSK
New P1 trial: Phase I study on the safety, tolerability, pharmacokinetics and pharmacodynamics of single-dose administration in healthy subjects and multiple-dose administration in COPD patients of HRS-9821 inhalation powder aerosol (EUDRACT) - Oct 30, 2025
P1, N=82, Not yet recruiting, Sponsor: West China Hospital of Sichuan University; Guangdong Hengrui Medicine Co., Ltd.
- | Review, Journal, Checkpoint inhibition: Clinical management of liver cancer patients with immune checkpoint inhibitors treatment. (Pubmed Central) - Oct 30, 2025
In this narrative review, we will highlight the major advancement of ICI in different stages of HCC and their implication in real world practice. The unmet need in the special population of liver cancer patients and the management of immune-related hepatitis will also be addressed.
- Keytruda (pembrolizumab) / Merck (MSD), plinabulin (BPI 2358) / BeyondSpring
A Phase 2 triplet study of plinabulin/docetaxel/pembrolizumab for metastatic NSCLC immediately after progression on immune-checkpoint-inhibitor alone or in combination: efficacy and biomarker analysis (Poster Hall (Exhibit Halls AB); Virtual) - Oct 30, 2025 - Abstract #SITC2025SITC_1642;
P2
The unmet need in the special population of liver cancer patients and the management of immune-related hepatitis will also be addressed. Whole blood analysis indicated higher proportions of activated CD4+/CD8+ T-cells post treatment.Trial Registration NCT05599789Ethics Approval The study was approved by the Ethics Committee of Peking Union Medical College Hospital (Ethics Approval Number: I-22PJ575).Consent No sensitive or identifiable information was contained in the abstract.Abstract 1330 Table 1View inline
- | AiTan (rivoceranib) / HLB Bio Group, celecoxib oral / Generic mfg.
Review, Journal: A comprehensive review of alkaloids in cancer therapy: focusing on molecular mechanisms and synergistic potential of piperine in colorectal cancer. (Pubmed Central) - Oct 30, 2025
Collectively, mechanistic insights, pharmacologic evaluations, and combinational strategies establish piperine as a promising multifunctional agent for CRC prevention and therapy. Nonetheless, standardized preclinical methodologies, detailed pharmacokinetic profiling, and well-structured early-phase clinical trials are critical to validate its translational potential and facilitate its integration into colorectal cancer management.
- | Review, Journal: Off-label use catalogue of tumor anti-angiogenic drugs in China: a narrative review. (Pubmed Central) - Oct 30, 2025
In addition, lenvatinib, pazopanib, sorafenib, apatinib, and sunitinib also have OLU recommendations for more than five cancer types. Our work offers an updated reference for the OLU of tumor AAT and highlights the need for further exploration into specific management measures for OLU in clinical practice.
- | Review, Journal: Antibody-drug conjugates targeting the cadherin, claudin and nectin families of adhesion molecules. (Pubmed Central) - Oct 30, 2025
In contrast, arcotatug tavatecan, garetatug rezetecan, sonesitatug vedotin and tecotabart vedotin are anti-CLDN18.2 ADCs in phase III clinical trials for the treatment of CLDN18.2-positive gastric or gastroesophageal junction adenocarcinomas, and raludotatug deruxtecan is an anti-CDH6 ADC in a phase II/III clinical trial for the treatment of platinum-resistant ovarian cancer. ADCs that target cell-cell adhesion molecules are a rapidly emerging class of cancer therapeutics, and bispecific ADCs and longitudinal companion diagnostics are emerging to further improve the clinical benefits of conventional ADCs.
- || Journal, Adverse events: BCR-ABL tyrosine kinase inhibitors associated acute kidney injury: a pharmacovigilance study based on the FAERS database with a case report. (Pubmed Central) - Oct 30, 2025
TKIs, including flumatinib, may cause AKI; however, FAERS-based disproportionality analysis does not indicate an increased renal safety signal compared to non-TKIs. Among TKIs, dasatinib and nilotinib have lower reporting disproportionality than imatinib does, suggesting a potential therapeutic advantage of their use for patients with kidney diseases.
- | Irene (pyrotinib) / Jiangsu Hengrui Pharma
Retrospective data, Journal, Real-world evidence: Survival analysis of pyrotinib in HER2-positive metastatic breast cancer: a multicenter real-world study. (Pubmed Central) - Oct 30, 2025
The updated analysis demonstrated that pyrotinib could be a promising treatment option in HER2-positive MBC with acceptable toxicity in the real world. Survival is still under assessment with longer follow-up.
- | etoposide IV / Generic mfg., AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma
Retrospective data, Journal, Real-world evidence: Real-world study of adebrelimab as first-line therapy for extensive-stage small cell lung cancer: a retrospective study. (Pubmed Central) - Oct 29, 2025
ECOG PS ?2, high metastatic burden, and elevated CRP independently predict poorer outcomes. Vigilant monitoring for hematologic toxicity and rare cardiotoxicity is warranted.
- | Tyvyt (sintilimab) / Innovent Biologics, Eli Lilly, AiRuiKa (camrelizumab) / HLB Bio Group
Retrospective data, Journal: Comparison of the short-term efficacy and safety of surgical operation of neoadjuvant sintilimab and camrelizumab, both in combination with chemotherapy in the treatment of resectable non-small cell lung cancer: a single-center retrospective cohort study. (Pubmed Central) - Oct 29, 2025
No differences were observed in the pCR rate (45.1% vs. 39.6%, P=0.45), the MPR rate (58.2% vs. 64.8%, P=0.36) and the ORR rate (75.8% vs. 67.0%, P=0.19) between the SG and CG groups. In the neoadjuvant chemoimmunotherapy treatment of resectable NSCLC, sintilimab and camrelizumab demonstrated comparable short-term efficacy and surgical safety when administered in conjunction with chemotherapy.
- | Irene (pyrotinib) / Jiangsu Hengrui Pharma, Enhertu (fam-trastuzumab deruxtecan-nxki) / Daiichi Sankyo, AstraZeneca
Review, Journal, IO biomarker: Advances in Targeted Therapy for Advanced Non-small Cell Lung Cancer with HER2 Mutation (Pubmed Central) - Oct 29, 2025
Future exploration trends are gradually shifting from single drugs to combination strategies, and are exploring more precise selection strategies as well as research on resistance mechanisms. These studies will provide a theoretical basis for clinical treatment strategies for advanced NSCLC with HER2 mutations, promoting the development of personalized therapy..
- || Biomarker, P2 data, Journal: Pathological response and metabolites' prognostic role in HER2-positive breast cancer treated with neoadjuvant pyrotinib, trastuzumab, nab-paclitaxel, and carboplatin: a single-arm phase II trial. (Pubmed Central) - Oct 29, 2025
These studies will provide a theoretical basis for clinical treatment strategies for advanced NSCLC with HER2 mutations, promoting the development of personalized therapy.. No abstract available
- | AiRuiYi (fluzoparib) / Jiangsu Hengrui Pharma, exemestane / Generic mfg.
Journal, BRCA Biomarker, PARP Biomarker: Case Report: Fluzoparib combined Exemestane in gBRCA2-mutated HR+/HER2- advanced breast cancer. (Pubmed Central) - Oct 27, 2025
The patient achieved a remarkably prolonged progression-free survival (PFS) of 37 months on this combination therapy, representing the longest period of disease control in her metastatic course. Although eventual progression occurred (new axillary lymph node metastasis and suspected hepatic recurrence), this case demonstrates the exceptional efficacy and durable disease control achievable with Fluzoparib plus Exemestane in a pretreated patient with gBRCA2-mutated HR+/HER2-advanced breast cancer, highlighting a promising therapeutic approach for this molecularly defined population.
- || P2 data, Journal: Perioperative camrelizumab and apatinib combined with chemotherapy for locally advanced gastric cancer in China: three-year survival outcomes of phase 2 randomized controlled trial. (Pubmed Central) - Oct 27, 2025
P2
Patients with LAGC (clinical T2-4, N+, M0) were randomly assigned to receive perioperative CA-SAP (camrelizumab and apatinib combined with nab-paclitaxel plus S-1 [SAP]) or SAP alone for three cycles preoperatively and five cycles postoperatively...Construction Funds for "High-level Hospitals and Clinical Specialties" of Fujian Province (No. [2021]76).
- AiRuiKa (camrelizumab) / HLB Bio Group
CHROMR Drives Immune Resistance and Lung Metastasis via Tumor Microenvironmental Remodeling in Triple-Negative Breast Cancer (Churchill Room) - Oct 26, 2025 - Abstract #ESMOIO2025ESMO_IO_525;
[2021]76). This study investigated the role of epigenetic regulation in remodeling the tumor immune microenvironment and promoting lung metastasis in TNBC.Methods We integrated single-cell full-length transcriptome sequencing and spatial transcriptomics to profile tumor
- Kaitanni (cadonilimab) / Akesobio
Efficacy and safety of first-line treatments in HER2-negative advanced gastric and gastroesophageal junction cancer (GC/GEJC): A systematic review and Bayesian network meta-analysis (Churchill Room) - Oct 26, 2025 - Abstract #ESMOIO2025ESMO_IO_499;
5. Regarding grade ?3 TRAEs, compared with chemo alone, sugemalimab + chemo (OR 1.145; 95% Crl 0.804, 1.627), SHR-1701 + chemo (OR 1.165; 95% Crl 0.863, 1.557), and tislelizumab + chemo (OR 1.174; 95% Crl 0.919, 1.51)showed better safety profile than other regimens.Conclusions Considering the balance between efficacy and safety, SHR - 1701 + chemo might be considered the preferred first-line treatment for patients with HER2-negative advanced GC/GEJC, particularly those with PD-L1 CPS ?1 or CPS ?5.
- AiRuiKa (camrelizumab) / HLB Bio Group
Camrelizumab combined with nab-paclitaxel as second-line therapy for advanced biliary tract cancer (BTC): A real-world study (Churchill Room) - Oct 26, 2025 - Abstract #ESMOIO2025ESMO_IO_449;
The most common adverse events were myelosuppression (notably leukopenia and neutropenia), jaundice, and elevated liver enzymes. No treatment-related deaths were reported.Conclusions The combination of camrelizumab with nab-paclitaxel as a second-line treatment demonstrated manageable toxicity and clinical efficacy in advanced BTC.
- Epidaza (chidamide) / Chipscreen, AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma
Efficacy of adebrelimab with chidamide, gemcitabine, and S-1 in locally advanced or metastatic pancreatic cancer: A phase II study (Churchill Room) - Oct 26, 2025 - Abstract #ESMOIO2025ESMO_IO_379;
P2
No treatment-related deaths were reported.Conclusions The combination of camrelizumab with nab-paclitaxel as a second-line treatment demonstrated manageable toxicity and clinical efficacy in advanced BTC. Table: 247P Adebrelimab + chidamide + gemcitabine + S-1(n=23) Median PFS, mo(95%CI) 8.0(6.9
- First line PD-L1/1 inhibition based therapies in elderly patients with ES-SCLC: a Systematic Literature Review and Network Meta-Analysis (Churchill Room) - Oct 26, 2025 - Abstract #ESMOIO2025ESMO_IO_375;
Currently, PD-1/PD-L1 inhibitors with platinum and etoposide (EP) have been adopted as standard first-line therapy and idemonstrated survival benefits in the overall population, while the magnitude of benefit and optimal agent in elderly patients remain unclear.Methods Following PRISMA-NMA guidelines, PubMed and ClinicalTrials.gov were searched up to 29 August 2025. Eligible RCTs compared first-line PD-L1 or PD-1 inhibitors
- AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma
Adebrelimab in the adjuvant treatment of esophageal squamous cell carcinoma: A randomized controlled clinical trial (PAIT-ESCC-0825) (Churchill Room) - Oct 26, 2025 - Abstract #ESMOIO2025ESMO_IO_308;
The stratification factor was postoperative pathological response to pCR (yes vs. no) and ever received immunotherapy (yes or no). Study Endpoints: Primary endpoint: Disease-Free Survival (DFS) & Secondary endpoints: Overall survival (OS), patient reported outcomes (PRO) and safety.
- Avastin (bevacizumab) / Roche, AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma
Hepatic arterial infusion or intravenous infusion of adebrelimab, combined with bevacizumab and hepatic arterial infusion chemotherapy as first-line treatment of advanced unresectable hepatocellular carcinoma: A multicenter, open label, randomized phase II clinical trial (Churchill Room) - Oct 26, 2025 - Abstract #ESMOIO2025ESMO_IO_307;
P2
Single cell Sequencing and RNA Sequencing of tumor biopsy and peripheral blood samples will be performed for predictive biomarker exploration. The trial is currently screening eligible subjects.
- Immune checkpoint inhibitors and hemophagocytic lymphohistiocytosis: Disproportionality analysis from FAERS (Churchill Room) - Oct 26, 2025 - Abstract #ESMOIO2025ESMO_IO_271;
Cases were grouped by PD-1 inhibitors (pembrolizumab, nivolumab, cemiplimab, sintilimab, tislelizumab, camrelizumab, retifanlimab, toripalimab) and PD-L1 inhibitors (atezolizumab, durvalumab, avelumab). Clinicians should remain vigilant for HLH
- Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka, AiRuiKa (camrelizumab) / HLB Bio Group
Clinical Study of Camrelizumab Combined with SOX in Adjuvant Therapy for Gastric or Gastroesophageal Junction Adenocarcinoma: Interim Report (Churchill Room) - Oct 26, 2025 - Abstract #ESMOIO2025ESMO_IO_265;
P2
Patients were assigned to receive either adjuvant therapy with camrelizumab (200mg intravenously on day 1), oxaliplatin, and S-1, or standard adjuvant chemotherapy...Systemic inflammation markers (RDW/NLR) may serve as potential prognostic biomarkers. However, due to the limited number of events, further follow-up is needed.
- AiRuiKa (camrelizumab) / HLB Bio Group
Camrelizumab combined with concurrent chemoradiotherapy for locally recurrent esophageal cancer: A single-arm, multi-center study (Churchill Room) - Oct 26, 2025 - Abstract #ESMOIO2025ESMO_IO_246;
P2
The most grade ?3 AEs was lymphocyte count decreased (19/41, 46.3%) and white blood cell count decreased (4/41, 9.8%).Conclusions Current results suggested the promising efficacy and acceptable safety of camrelizumab combined with CCRT in pts with locally recurrent esophageal cancer. The study enrollment is ongoing, and further survival and safety data will be reported in the future.
- AiRuiKa (camrelizumab) / HLB Bio Group
Thalidomide for preventing camrelizumab-induced reactive cutaneous capillary endothelial proliferation (RCCEP): A multicenter, randomized clinical trial (Churchill Room) - Oct 26, 2025 - Abstract #ESMOIO2025ESMO_IO_240;
P2
The overall tolerability of thalidomide was good. The dose of 100 mg/day exhibited better preventive effect than 50 mg/day.
- retlirafusp alfa (SHR-1701) / Jiangsu Hengrui Pharma
SHR-1701 Plus CAPOX for advanced gastric or gastroesophageal junction adenocarcinoma with high-risk features: Results from a phase III study (Whittle Room) - Oct 26, 2025 - Abstract #ESMOIO2025ESMO_IO_126;
P3
For diffuse-type histology, OS was 16.4 months (95% CI, 12.5- not estimable) versus 9.5 months (95% CI, 5.9-12.4; HR, 0.50; 95% CI, 0.26-0.95). In patients with ?1 high-risk feature, OS was 14.4 months (95% CI, 12.7-16.8) versus 10.1 months (95% CI, 8.8-11.7; HR, 0.62; 95% CI, 0.49-0.78).Conclusions SHR-1701 plus CAPOX demonstrated OS benefit across high-risk subgroups, including patients with liver metastasis, diffuse-type histology, and peritoneal metastasis.
- | AiRuiYi (fluzoparib) / Jiangsu Hengrui Pharma
Journal, PARP Biomarker: Hepatitis B virus core protein promotes liver cancer progression by stabilizing CANX and suppressing IRF7 transcription. (Pubmed Central) - Oct 26, 2025
We showed that a candidate compound fluzoparib effectively suppressed HBC-positive liver cancer cells in vitro and in vivo. Overall, this study underscores the crucial role of CANX and its regulatory mechanisms in promoting HBC-mediated liver cancer progression and reveals the therapeutic potential of targeting CANX in HBV infection-caused liver cancer.
- || AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / HLB Bio Group
P2 data, Journal: Efficacy and safety of neoadjuvant camrelizumab and apatinib combined with chemotherapy in stage IIIA (N2) NSCLC: a multi-center, single-arm, phase II trial. (Pubmed Central) - Oct 26, 2025
P=N/A
Overall, this study underscores the crucial role of CANX and its regulatory mechanisms in promoting HBC-mediated liver cancer progression and reveals the therapeutic potential of targeting CANX in HBV infection-caused liver cancer. The synergistic application of chemotherapy with camrelizumab and apatinib showed clinically meaningful anti-tumor activity and manageable safety, with few hematologic toxicities, and might be a promising therapeutic alternative for individuals with resectable stage IIIA (N2) NSCLC.
- || AiRuiKang (dalpiciclib) / Jiangsu Hengrui Pharma, Irene (pyrotinib) / Jiangsu Hengrui Pharma, Herceptin (trastuzumab) / Roche
P2 data, Journal: Letter to the editor--efficacy and Safety of Neoadjuvant Treatment of Trastuzumab and Pyrotinib Plus Dalpiciclib in HR-negative/HER2-positive Breast Cancer an Exploratory, Open-label Phase II Study. (Pubmed Central) - Oct 24, 2025
The synergistic application of chemotherapy with camrelizumab and apatinib showed clinically meaningful anti-tumor activity and manageable safety, with few hematologic toxicities, and might be a promising therapeutic alternative for individuals with resectable stage IIIA (N2) NSCLC. No abstract available
- | Tagrisso (osimertinib) / AstraZeneca, AiRuiKa (camrelizumab) / HLB Bio Group
Journal, PD(L)-1 Biomarker, IO biomarker, P53mut: Synergistic camrelizumab therapy inhibits P53-mutant osimertinib-resistant solid lung adenocarcinoma via the TGF-? signaling pathway. (Pubmed Central) - Oct 24, 2025
Solid osimertinib-resistant LACs by ICI can be beneficial through the inhibition of TGF-? signaling pathway.
- | AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / HLB Bio Group
Journal: Case report: Abscopal response and reversal of PD-1 resistance in a patient with nephroblastoma following radiofrequency ablation. (Pubmed Central) - Oct 24, 2025
Follow-up confirmed PR of the pleural lesion and total disappearance of pleura-irritative symptoms. This case demonstrates a potential abscopal effect induced by RFA, in which local treatment of one tumor site coincided with systemic regression of distant, untreated lesions and reversal of prior PD-1 inhibitor resistance.
- ||| recaticimab (SHR-1209) / Jiangsu Hengrui Pharma
Biomarker, P3 data, Journal: Recaticimab in adult heterozygous familial hypercholesterolemia (REMAIN-3): A multicentre, randomised, double-blind, placebo-controlled phase 3 study. (Pubmed Central) - Oct 24, 2025
P3
This case demonstrates a potential abscopal effect induced by RFA, in which local treatment of one tumor site coincided with systemic regression of distant, untreated lesions and reversal of prior PD-1 inhibitor resistance. Recaticimab significantly lowered the LDL-C level compared with placebo, with an acceptable safety profile, providing a new effective treatment option for patients with inadequately controlled HeFH.
- | Irene (pyrotinib) / Jiangsu Hengrui Pharma
Journal: Pyrotinib inhibits the tumorigenicity of HER2-positive non-small cell lung cancer by inducing ARIH1/ubiquitin/lysosome-dependent degradation of HER2. (Pubmed Central) - Oct 22, 2025
Recaticimab significantly lowered the LDL-C level compared with placebo, with an acceptable safety profile, providing a new effective treatment option for patients with inadequately controlled HeFH. No abstract available
- || NovaTears (perfluorohexyloctane) / Novaliq, Bausch Health, AFT Pharma
Enrollment closed: A Study to Evaluate Concomitant Perfluorohexyloctane Use With Contact Lens Wear (clinicaltrials.gov) - Oct 21, 2025
P4, N=100, Active, not recruiting, Sponsor: Bausch & Lomb Incorporated
No abstract available Recruiting --> Active, not recruiting
- | Ruiqin (henagliflozin) / Jiangsu Hengrui Pharma
Journal: Henagliflozin Increases Serum and Salivary Levels of High-Molecular-Weight Adiponectin in Patients with Type 2 Diabetes in the Community. (Pubmed Central) - Oct 21, 2025
In order to reveal the influence factors of adiponectin in serum and saliva, linear stepwise regression analysis showed that waist circumference was an independent risk factor for adiponectin in serum (95% CI: -0.087, -0.015; P < 0.05), and gender was an independent risk factor for adiponectin in saliva (95% CI: -4.663, -0.529; P < 0.05). In our study, serum and salivary HMW adiponectin levels were decreased in patients with T2DM, and Sodium-glucose co-transporter-2 (SGLT2) inhibitors could improve serum and salivary HMW adiponectin levels after treatment, which is expected to be a major target for diabetes treatment.
- | AiRuiKa (camrelizumab) / HLB Bio Group
Journal: Psoriasis caused by camrelizumab in a patient with esophageal cancer: a case report. (Pubmed Central) - Oct 20, 2025
The condition improved following the discontinuation of camrelizumab and treatment with a topical glucocorticoid and a vitamin D3 derivative ointment. At 6-month follow-up, the patient showed no recurrence of psoriatic lesions or tumor progression.
- HRS-7535 / Kailera Therapeutics
Efficacy and Safety of the Oral Small-Molecule GLP-1 Receptor Agonist HRS-7535 in Patients with Diabetic Kidney Disease (Grand Ballroom C, Convention Center) - Oct 18, 2025 - Abstract #KIDNEYWEEK2025KIDNEY_WEEK_5349;
P2
At 6-month follow-up, the patient showed no recurrence of psoriatic lesions or tumor progression. In patients receiving standard of care (SOC), including renin
- HRS-5965 / Jiangsu Hengrui Pharma
Multicenter, Randomized Phase 2 Study Evaluating the Efficacy and Safety of HRS-5965 in Patients with Primary IgAN (Exhibit Hall, Convention Center) - Oct 18, 2025 - Abstract #KIDNEYWEEK2025KIDNEY_WEEK_4920;
10%) in HRS-5965 groups were upper respiratory tract infection and hyperuricemia. Conclusion HRS-5965 showed proteinuria reduction in IgAN patients with acceptable safety and tolerability, which will further support the evaluation of HRS-5965 in phase 3 clinical trials.
- HRS-1780 / Jiangsu Hengrui Pharma
Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Evaluating the Efficacy and Safety of HRS-1780 Tablets in Patients with CKD (Exhibit Hall, Convention Center) - Oct 18, 2025 - Abstract #KIDNEYWEEK2025KIDNEY_WEEK_4892;
The incidence of hyperkalaemia (defined by serum K + > 5.5 mmol/L) was 4.5% and 15.6% with HRS-1780 10 mg and 20 mg groups, respectively. Conclusion Treatment of HRS-1780 showed good efficacy and safety profile in CKD patients.